CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: July 3, 2012
Result type: Reports
Project Number: SR0284-000
Product Line: Reimbursement Review

Generic Name: Lurasidone

Brand Name: Latuda

Manufacturer: Sunovion Pharmaceuticals Inc.

Therapeutic Area: Schizophrenia

Indications: schizophrenia

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: January 23, 2013

Recommendation Type: Do not list